Biography
Stacy Enxing Seng (born 1964, US citizen) has been a non-executive member of the Board of Directors since 2014 and serves on the Nomination and Compensation Committee. She became Vice Chair of the Board of Directors at the 2021 AGM.
She previously served as President of Covidien’s Vascular Therapies division. Stacy Enxing Seng joined Covidien as president of its vascular therapies division in July 2010 through its acquisition of ev3 where she was a founding member and executive officer responsible for leading ev3’s Peripheral Vascular Division from inception. She has also held various positions at Boston Scientific, SCIMED Life Systems Inc., Baxter Healthcare, and American Hospital Supply.
With her broad experience in the medical technology sector and her strong track record in growing startups and leading multinational companies, she brings further important perspectives to the Group. Her expertise in working with regulatory agencies around the globe brings valuable insight to the Board of Directors.
Stacy Enxing Seng received an MBA from Harvard University and has a Bachelor of Arts in Public Policy from Michigan State University, USA.
Outside mandates
Listed companies:
- Member of the Board of Directors of LivaNova, Inc.
Other mandates:
- Chair of the Board of Directors of Cala Health
- Executive Chair of the Board of Directors of Contego Inc.
- Member of the Board of Directors of Corza, Inc.
- Member of the Board of Directors of Imperative Care
- Operating Partner of Lightstone Ventures
Meeting attendance during the financial year 2024/25
- Regular Board of Directors meetings: 5 out of 5 meetings attended
- Additional calls of the Board of Directors: 1 out of 1 calls attended
- Nomination and Compensation Committee: 5 out of 5 meetings and 1 out of 1 calls attended
Holdings as per 31.03.2025
- Shares: 10,822
- Restricted Shares1): 2,969